Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
Completed · Phase 2 · NCT04744831
Conditions: Advanced Colorectal Cancer
At a glance
- Research payments reported, 2025
- $83,338
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 122
About the trial
- Sponsor
- Daiichi Sankyo (with AstraZeneca)
- Tested
- DS-8201a 5.4 mg/kg Q3W (drug), DS-8201a 6.4 mg/kg Q3W (drug)
- Dates
- Started 2021-03-05; completion 2024-12-04
- Results posted
- Yes
This study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor 2 (HER2)-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC).
From ClinicalTrials.gov, last updated 2026-01-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $83,338 in research payments for this study in 2025 (11 payments).
Products named: Enhertu
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- John H. Strickler, MD Hematology & Oncology · Jacksonville, FL
- Kanwal P. Raghav, M.D. Medical Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Duke University $81,853
- Ut MD Anderson Cancer Center $1,485
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.